Seegene

Seegene Equity

The The Equity of Seegene (096530.KQ) as of Oct 19, 2026 is 1.02 T KRW. In the previous year, The Equity was 978.63 B KRW — a change of 3.76% (higher).

Equity

1.02 TKRW

YoY

3.76%

Last updated:

In 2025, Seegene's equity was 1.02 T KRW, a 3.76% increase from the 978.63 B KRW equity in the previous year.

The Seegene Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
128.03 B KRW
Jan 1, 2019
152.55 B KRW
Jan 1, 2020
645.32 B KRW
Jan 1, 2021
1.08 T KRW
Jan 1, 2022
1.15 T KRW
Jan 1, 2023
1.03 T KRW
Jan 1, 2024
978.63 B KRW
Jan 1, 2025
1.02 T KRW
The Seegene Equity history
YEAREquityYoY
1.02 TKRW+3.76%
978.63 BKRW-4.78%
1.03 TKRW-10.46%
1.15 TKRW+6.14%
1.08 TKRW+67.58%
645.32 BKRW+323.02%
152.55 BKRW+19.15%
128.03 BKRW+2.39%
125.04 BKRW-11.93%
141.97 BKRW+5.09%
135.09 BKRW+42.58%
94.75 BKRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Seegene Stock analysis

What does Seegene do? Seegene Inc., headquartered in Seoul, South Korea, is a biotechnology company listed on the stock market since 2010. It specializes in manufacturing and distributing molecular diagnostics and reagents, offering products for infectious pathogens detection, including respiratory and sexually transmitted diseases, HPV, drug resistance, SNP analysis, and cancer somatic mutation testing. The company provides automatic real-time detection instruments under brand names Seeplex, Anyplex, and Magicplex, serving both domestic and international markets. Seegene is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Seegene's Equity

Seegene's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Seegene's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Seegene's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Seegene's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Seegene’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Seegene stock

The Equity of Seegene is 1.02 T KRW in 2025.

The Equity of Seegene changed from 978.63 B KRW to 1.02 T KRW, representing a 3.76% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of The Equity Seegene since 2006 – with annual values, charts, and detailed analysis.

The Equity's KRW is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Seegene historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Seegene

All Key Metrics — Seegene